Novartis has acquired Avidity Biosciences, Inc. for an undisclosed amount, signaling a strategic expansion into advanced RNA therapeutics. Avidity Biosciences is a biotechnology company focused on revolutionizing the delivery of RNA therapeutics through its proprietary Antibody Oligonucleotide Conjugate (AOC) platform. This innovative platform is designed to combine the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide-based therapies, aiming to more effectively target underlying genetic drivers of diseases.
Avidity has been advancing its science with a pipeline initially focused on rare muscle diseases, including myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD). The company's vision is to profoundly improve people’s lives by delivering a new class of targeted RNA therapeutics. Novartis, a global pharmaceutical leader, consistently seeks to bolster its portfolio with cutting-edge scientific approaches to address unmet medical needs.
This acquisition is a strategic move for Novartis to integrate Avidity's disruptive AOC platform and pipeline. The platform's ability to deliver RNA therapeutics to previously inaccessible tissues and cell types aligns with Novartis’s commitment to pioneering new treatment modalities. The purchase is expected to enhance Novartis’s capabilities in genetic medicine, leveraging Avidity's specialized expertise in targeted RNA delivery for broad therapeutic application.
The combined strengths of Avidity’s scientific innovation and Novartis’s extensive research and development resources, global clinical development capabilities, and market presence are anticipated to accelerate the advancement of these novel therapies. This corporate acquisition aims to significantly impact the development of breakthrough treatments, ultimately enhancing the ability to provide new options for patients with genetically driven diseases.